Goodrx Holdings, Inc. (GDRX)
NASDAQ:GDRX
Want to see GDRX full AI Analyst Report?
Top Page
GoodRx Holdings
(NASDAQ:GDRX)
Select Model
Select Model
Rating:72Outperform
Price Target:
$3.00
▲(32.16% Upside)
Action:Upgraded
Date:05/09/26
The score is driven primarily by improved financial quality (delevered balance sheet, sustained cash generation, and positive profitability) and supportive earnings-call signals (raised 2026 guidance and rapid Pharma Direct growth). These positives are tempered by weak legacy segment trends and top-line pressure, plus overbought technical conditions and only moderate valuation support.
Positive Factors
Balance Sheet Deleveraging
GoodRx’s sharp reduction in leverage to roughly 0.09–0.10 materially lowers financial risk and increases strategic optionality. With a light debt load the company can fund growth initiatives, absorb cyclical shocks, and allocate cash to product investment or opportunistic M&A without immediate refinancing pressure.
Negative Factors
Legacy Prescription Transactions Decline
A persistent 24% YoY drop in the core PTR business indicates secular pressure in the legacy model. Continued erosion reduces predictable fee-based revenues and forces reliance on newer segments to replace high-volume transaction economics, increasing execution risk for total revenue recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Deleveraging
GoodRx’s sharp reduction in leverage to roughly 0.09–0.10 materially lowers financial risk and increases strategic optionality. With a light debt load the company can fund growth initiatives, absorb cyclical shocks, and allocate cash to product investment or opportunistic M&A without immediate refinancing pressure.
Read all positive factors
GoodRx Holdings Key Performance Indicators (KPIs)
Any
Monthly Active Consumers
Shows the number of unique users engaging with the platform each month, highlighting user retention, platform popularity, and potential for monetization.
Shows the number of unique users engaging with the platform each month, highlighting user retention, platform popularity, and potential for monetization.
Data provided by:
The Fly
The FlyGoodRx Holdings (GDRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$968.61M
Dividend YieldN/A
Average Volume (3M)1.72M
Price to Earnings (P/E)49.2
Beta (1Y)0.81
Revenue Growth-1.19%
EPS Growth-21.87%
CountryUS
Employees738
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.09
Shares Outstanding104,711,190
10 Day Avg. Volume1,620,631
30 Day Avg. Volume1,715,885
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)1.57
Price to Sales (P/S)1.21
P/FCF Ratio5.87
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue1.08
Enterprise Value/Gross Profit1.25
Enterprise Value/Ebitda4.87
Forecast
1Y Price Target
$3.09Price Target Upside36.12% Upside
Rating ConsensusHold
Number of Analyst Covering13
EPS Forecast (FY)0.31
Revenue Forecast (FY)$775.88M
GoodRx Holdings Business Overview & Revenue Model
Company Description
GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provide...
How the Company Makes Money
GoodRx primarily generates revenue by facilitating prescription transactions and related healthcare services through its platform. A major revenue stream comes from prescription discount programs: when a consumer uses a GoodRx code/coupon at a pha...
GoodRx Holdings Earnings Call Summary
Earnings Call Date:May 06, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Positive
The call balanced material near-term headwinds in the legacy prescription transactions business (PTR) — notably a 24% YoY decline in PTR revenue and persistent unit-economics pressure — against strong and accelerating growth in strategic areas (Pharma Direct up 82% YoY, subscriptions +16% YoY), improved operational scalability in e-commerce, and a raised full-year guidance. Management emphasized durable strategy execution, margin discipline (30% adjusted EBITDA margin in Q1), and momentum in Pharma Direct and condition-specific subscriptions. While legacy PTR trends and macro/regulatory uncertainty are notable risks, the company’s improved guidance, profitable quarter, and rapid Pharma Direct expansion weigh positively.Positive Updates
Q1 Revenue and Profitability
Reported revenue of $194 million in Q1 2026 and adjusted EBITDA of $58.3 million, representing a 30% adjusted EBITDA margin.
Negative Updates
Decline in Prescription Transactions Revenue (PTR)
Prescription transactions revenue was $113.7 million in Q1, down 24% year-over-year, driven by lapping impacts from 2025 and unit economics pressure in the legacy PTR business.
Read all updates
Q1-2026 Updates
Positive
Negative
Q1 Revenue and Profitability
Reported revenue of $194 million in Q1 2026 and adjusted EBITDA of $58.3 million, representing a 30% adjusted EBITDA margin.
Read all positive updates
Company Guidance
GoodRx raised full-year 2026 guidance, now expecting revenue of $765–$785 million and adjusted EBITDA of at least $235 million, driven primarily by stronger-than-expected Pharma Direct performance; in Q1 the company reported revenue of $194 million, adjusted EBITDA of $58.3 million (30% margin), prescription transactions revenue of $113.7 million (down 24% YoY) with monthly active consumers roughly flat sequentially at 5.3 million, Pharma Direct revenue of $52.2 million (up 82% YoY and now expected to grow >50% YoY for 2026), subscription revenue of $24.4 million (up 16% YoY) as subscription plans returned to YoY growth, over 125 self-pay programs live, e-commerce order volume and claims more than doubled quarter-over-quarter, and direct contracts in place with 9 of the top 10 retail pharmacies.GoodRx Holdings Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
82
Very Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 787.89M | 796.85M | 792.32M | 750.26M | 766.55M | 745.42M |
| Gross Profit | 681.98M | 739.26M | 744.11M | 683.34M | 701.48M | 698.71M |
| EBITDA | 175.17M | 184.36M | 153.92M | 108.82M | 65.19M | 48.00M |
| Net Income | 20.56M | 30.44M | 16.39M | -8.87M | -32.83M | -25.25M |
Balance Sheet | ||||||
| Total Assets | 2.02B | 1.40B | 1.39B | 1.59B | 1.60B | 1.61B |
| Cash, Cash Equivalents and Short-Term Investments | 235.71M | 261.82M | 448.35M | 672.30M | 757.16M | 941.11M |
| Total Debt | 58.93M | 59.54M | 543.39M | 711.07M | 717.02M | 702.33M |
| Total Liabilities | 1.40B | 787.80M | 663.41M | 826.84M | 789.80M | 775.95M |
| Stockholders Equity | 621.99M | 616.26M | 724.66M | 761.96M | 814.83M | 831.68M |
Cash Flow | ||||||
| Free Cash Flow | 131.64M | 164.38M | 113.55M | 82.53M | 91.57M | 144.32M |
| Operating Cash Flow | 170.33M | 167.90M | 183.89M | 138.29M | 146.78M | 178.78M |
| Investing Cash Flow | -89.73M | -119.96M | -70.35M | -55.77M | -210.50M | -178.73M |
| Financing Cash Flow | -145.87M | -234.47M | -337.50M | -167.40M | -120.23M | -30.53M |
GoodRx Holdings Technical Analysis
Positive
2.27
Price Trends
2.34
Positive
2.37
Positive
2.99
Negative
Market Momentum
0.10
Negative
66.66
Neutral
75.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GDRX, the sentiment is Positive. The current price of 2.27 is below the 20-day moving average (MA) of 2.60, below the 50-day MA of 2.34, and below the 200-day MA of 2.99, indicating a neutral trend. The MACD of 0.10 indicates Negative momentum. The RSI at 66.66 is Neutral, neither overbought nor oversold. The STOCH value of 75.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GDRX.
GoodRx Holdings Risk Analysis
GoodRx Holdings disclosed 2 risk factors in its most recent earnings report. GoodRx Holdings reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GoodRx Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $978.52M | -166.67 | -2.81% | ― | 49.36% | 83.76% | |
72 Outperform | $968.61M | 49.20 | 3.31% | ― | -1.19% | -21.87% | |
68 Neutral | $95.61M | 10.08 | 16.87% | ― | 10.34% | ― | |
68 Neutral | $564.00M | 45.34 | 3.87% | ― | 14.05% | ― | |
57 Neutral | $147.70M | ― | -35.14% | ― | -9.29% | 46.89% | |
54 Neutral | $1.19B | -7.86 | -12.37% | ― | -1.50% | 83.75% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
GDRX
GoodRx Holdings
2.97
-0.84
-22.05%
CCLD
CareCloud
2.32
0.20
9.43%
TDOC
Teladoc
7.51
0.53
7.59%
PHR
Phreesia
9.45
-14.98
-61.32%
AMWL
American Well
9.46
2.55
36.90%
OMDA
Omada Health, Inc.
17.82
-4.78
-21.15%
GoodRx Holdings Corporate Events
Executive/Board Changes
GoodRx Names Thomas Chan Chief Accounting Officer
Positive
Apr 24, 2026
GoodRx Holdings, Inc. has appointed Thomas Chan as its Chief Accounting Officer and principal accounting officer, effective April 23, 2026, elevating him from his prior role as Vice President, Corporate Controller. Chan, 40, joined the company in ...
Executive/Board Changes
GoodRx Reshapes Board After Director Resignation and Reclassification
Neutral
Apr 3, 2026
On March 31, 2026, GoodRx Holdings director Ian T. Clark resigned from the company’s board and its Nominating Governance Committee, with the company noting his departure did not stem from any disagreement over operations, policies or practi...
Executive/Board Changes
GoodRx Chief Accounting Officer Resigns for New Opportunity
Neutral
Mar 27, 2026
On March 24, 2026, GoodRx Holdings, Inc. announced that Chief Accounting Officer Romin Nabiey submitted his resignation, effective April 3, 2026, to pursue other opportunities, in a move that the company said was not related to any disagreement ov...
Executive/Board Changes
GoodRx Awards Performance-Based Bonus to Chief Accounting Officer
Positive
Mar 6, 2026
On March 3, 2026, GoodRx Holdings, Inc.’s board of directors approved a discretionary cash bonus of $72,918 for 2025 performance for Romin Nabiey, the company’s chief accounting officer. The award highlights the board’s recogniti...
Executive/Board Changes
GoodRx Announces Resignation of Board Member Dipanjan Deb
Neutral
Feb 27, 2026
On February 26, 2026, GoodRx Holdings, Inc. disclosed that board member Dipanjan Deb resigned from its Board of Directors, effective the same day. The company reported that Deb’s departure was not due to any disagreement with management or w...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.